drugset / Trial / NCT00323687

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

NCT00323687

Phase 4 Completed 50 enrolled Gilead Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

There is an unmet medical need for potent ART regimens that make adherence to treatment even easier due to QD dosing, offer a good tolerability profile and fit into the daily life of patients.

Timeline

Start
2004-09
Primary completion
2006-10
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Small molecule 200 mg Oral
Subject Tenofovir Small molecule 300 mg Oral